Short-nosed dogs may soon breathe more easily thanks to a new injection developed by Australian scientists to help treat serious breathing problems common in flat-faced breeds.

Almost half of all Pugs, French Bulldogs, and British Bulldogs suffer from Brachycephalic Obstructive Airway Syndrome (BOAS), a chronic condition that affects breathing, eating, exercise, and sleep. In severe cases, it can shorten a dog’s life by up to four years.

Experts say decades of selective breeding for the popular flat-faced appearance have unfortunately caused major respiratory issues in these breeds.

Many affected dogs require surgery to widen their nostrils and remove excess throat tissue to improve airflow.

One dog named Pugtato had severe breathing difficulties, with his owner Joanna Herceg saying she feared he might die. Although surgery helped slightly, he continued to struggle.

Pugtato later became part of an early trial involving six pugs and bulldogs testing a new treatment called SnoreTox-1, developed by biotech company Snoretox and RMIT University in Melbourne.

The treatment involves an injection under the tongue and is designed to strengthen airway muscles, helping keep the throat open and improve breathing.

Owners reported reduced breathing noise and easier movement within 10 days of treatment, while Pugtato showed improvement within just a few days.

His owner said he transformed from a dog that struggled daily into one that is active, happy, playful, and breathing far better.

Researchers say the treatment has been in development for 15 years, with some dogs experiencing benefits for more than six months.

Further trials are expected later this year, with hopes of gaining approval for wider use in the future.